Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3

International Archives of Allergy and Immunology
T TsujimuraY Kanakura

Abstract

The c-kit protooncogene encodes a receptor tyrosine kinase that mediates signals required for differentiation, proliferation and survival of mast cells. We have already shown the constitutive activation of c-kit receptor tyrosine kinase (KIT) in a human mast cell leukemia line (HMC-1) and a murine mastocytoma cell line (P-815). We here examined whether such constitutive activation of KIT occurred in the rat tumor mast cell line RBL-2H3 as well, which is frequently used as a tool for studying functions of mast cells. In RBL-2H3 cells, KIT was constitutively phosphorylated on tyrosine and activated in the absence of autocrine production of its ligand, stem cell factor (SCF). Sequencing analysis revealed that one of c-kit genes of RBL-2H3 cells had a point mutation, resulting in amino acid substitution of Tyr for Asp in codon 817. When rat wild-type c-kit cDNA and mutant-type c-kit cDNA encoding KITTyr817 were transfected into cells of a human embryonic kidney cell line (293T), only mutant form KITTyr817 was constitutively phosphorylated on tyrosine and activated in the absence of SCF. Since mutations at the same Asp codon constitutively activated KIT in all the human HMC-1, murine P-815, and rat RBL-2H3 cell lines, and since the ...Continue Reading

Citations

Aug 12, 2009·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·Egle Passante, Neil Frankish
Jun 20, 2002·Cancer Genetics and Cytogenetics·Avery A Sandberg, Julia A Bridge
Apr 21, 1999·Experimental Hematology·C A LondonE N Geissler
Mar 12, 2002·British Journal of Haematology·John T Reilly
Jul 10, 2001·British Journal of Haematology·F M Abu-DuhierJ T Reilly
May 17, 2008·Avian Pathology : Journal of the W.V.P.A·S Hafner, K Latimer
Dec 15, 2005·The Journal of Experimental Medicine·Jacques P ZappullaRoland S Liblau
Mar 4, 2000·The American Journal of Dermatopathology·M J RegueraL Ferrer
Oct 25, 2006·Molecular and Cellular Biology·Zhifu XiangMichael H Tomasson
Jul 5, 2005·Acta Haematologica·Cem Akin
Sep 1, 2007·Proceedings of the Japan Academy. Series B, Physical and Biological Sciences·Yukihiko KitamuraAkihiko Ito
Aug 13, 2002·American Journal of Veterinary Research·Gillian DankCheryl A London
Feb 17, 1999·Proceedings of the National Academy of Sciences of the United States of America·B J LongleyY Ma
Sep 24, 1999·Leukemia & Lymphoma·L K AshmanA C Cambareri
Mar 18, 2000·Leukemia & Lymphoma·L K AshmanA C Cambareri
Apr 9, 2004·Cancer Investigation·Anette DuensingJonathan A Fletcher
Jun 20, 2006·Best Practice & Research. Clinical Haematology·A PardananiP Valent
Jul 26, 2000·Hematology/oncology Clinics of North America·M L Taylor, D D Metcalfe
Mar 4, 2005·The American Journal of Pathology·Atsuhito OkayaTohru Tsujimura
Sep 11, 2004·Biochemical and Biophysical Research Communications·Hiroki SasanumaRyo Goitsuka
Feb 16, 1996·The Journal of Biological Chemistry·Y MoriyamaY Kanakura
Apr 1, 2004·Journal of Veterinary Diagnostic Investigation : Official Publication of the American Association of Veterinary Laboratory Diagnosticians, Inc·Cameron L R JonesCheryl A London
Aug 2, 2001·Journal of Veterinary Diagnostic Investigation : Official Publication of the American Association of Veterinary Laboratory Diagnosticians, Inc·D ZemkeV Yuzbasiyan-Gurkan
Dec 14, 2004·Journal of Veterinary Diagnostic Investigation : Official Publication of the American Association of Veterinary Laboratory Diagnosticians, Inc·Rosario PreziosiGiuseppe Sarli
Aug 9, 2001·International Journal of Surgical Pathology·Brian P. RubinChristopher D. M. Fletcher
Apr 12, 2001·The British Journal of Dermatology·K Hartmann, B M Henz
Sep 6, 2006·The Journal of Veterinary Medical Science·Emi OhashiNobuo Sasaki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.